Novartis Reports Result of Kisqali (ribociclib) + Endocrine Therapy in P-III MONALEESA-7 Study for HR+/HER2- Advanced Breast Cancer #ASCO2019

 Novartis Reports Result of Kisqali (ribociclib) + Endocrine Therapy in P-III MONALEESA-7 Study for HR+/HER2- Advanced Breast Cancer #ASCO2019

Novartis Reports Result of Kisqali (ribociclib) + Endocrine Therapy in P-III MONALEESA-7 Study for HR+/HER2- Advanced Breast Cancer #ASCO2019

Shots:

  • The P-III MONALEESA-7 study results involves assessing of Kisqali in combination with endocrine therapy (goserelin + aromatase inhibitor/tamoxifen) vs endocrine therapy as monothx. in pre- and perimenopausal women with HR+/HER2- advanced or metastatic breast cancer
  • The P-III MONALEESA-7 study resulted in improving survival rate @42mos. (70.2% vs 46.0%), 30%/20.9% reduction in risk of death, no new safety signals were observed, presented at ASCO 2019 respectively
  •  Kisqali is the CDK4/6 inhibitor, currently evaluated in P-III NATALEE study with endocrine therapy as an adjuvant treatment of HR+/HER2- early breast cancer and is approved in 75+ countries including the US & EU for the same indication

Click here to read full press release/ article | Ref: Novartis | Image:  Coroflot

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post